Drug intelligence / Profile preview

ZK094

Development stage: Preclinical
Lead developer: Lee's Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

ZK094 is a preclinical-stage drug candidate being developed by Lee's Pharmaceutical for the treatment of pulmonary hypertension. It is part of the company's internal research and development pipeline focused on cardiovascular and pulmonary diseases. As of 2024, specific details regarding the molecule's chemical structure, molecular target, and precise mechanism of action remain proprietary and have not been disclosed in public clinical or scientific literature. The program is currently undergoing early-stage evaluation to determine its safety and efficacy profile prior to potential clinical trial initiation.

Beyond the preview

Go deeper on ZK094.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZK094.

Explore the full profile